Rheumatoid Arthritis currently affects around 35,000 people in Scotland. It causes joint pain, swelling and stiffness, affecting a patient’s mobility and interfering with their quality of life and ability to work. Patients may need long-term treatment to control their symptoms and reduce joint damage.
Despite the fact that treatment options have improved in the last 20 years, the UK National Audit Office estimates that rheumatoid arthritis costs the NHS around £560 million every year. A significant part of this cost is down to failed treatments.
Professor Iain McInnes of the University of Glasgow explains how a precision medicine project being carried out by Stratified Medicine Scotland Innovation Centre could help both patients and the NHS.
Today (Monday 18 June) MSP Johann Lamont visited the Stratified Medicine Scotland Innovation Centre (SMS-IC) in Glasgow, to see first-hand how it is bringing together industry innovators, clinicians and world-class researchers together to work on precision medicine.
Precision medicine ensures drugs are specifically targeted to a person’s genetic makeup rather than a “one size fits all” approach. This helps get the right treatment to the right person at the right time, improving outcomes for patients and slashing the costs of ineffective treatments, saving lives and scarce NHS resources.
A new collaboration in genomic medicine sees Scotland join AstraZeneca’s global genomics initiative – further demonstrating Scotland’s ability to attract major industry projects.